Recombinant influenza virus expressing a fusion protein neutralizing epitope of respiratory syncytial virus (RSV) confers protection without vaccine-enhanced RSV disease

Antiviral Research

Volumn 115, Issue , 2015, Pages 1-8

  Lee, Yu Na ^a   Hwang, Hye Suk ^a   Kim, Min Chul ^a,b   Lee, Young Tae ^a   Lee, Jong Seok ^a   Moore, Martin L ^c,d   Kang, Sang Moo ^a  

^a GEORGIA STATE UNIVERSITY   (United States)

^b Animal Plant and Fisheries Quarantine and Inspection Agency   (South Korea)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d CHILDREN'S HEALTHCARE OF ATLANTA   (United States)

Author keywords

F protein; Influenza virus; Neutralizing epitope vaccine; Recombinant; Respiratory syncytial virus; Viral vector

Indexed keywords

HYBRID PROTEIN; RESPIRATORY SYNCYTIAL VIRUS 243 294 NEUTRALIZING EPITOPE HEMAGGLUTININ FUSION PROTEIN; UNCLASSIFIED DRUG; VIRUS VECTOR; EPITOPE; FORMALDEHYDE; GAMMA INTERFERON; INACTIVATED VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; INTERLEUKIN 4; NEUTRALIZING ANTIBODY; RESPIRATORY SYNCYTIAL VIRUS VACCINE; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; EOSINOPHIL; FEMALE; HUMAN RESPIRATORY SYNCYTIAL VIRUS; INFLUENZA VIRUS; LOEFFLER PNEUMONIA; MOUSE; NONHUMAN; RESPIRATORY SYNCYTIAL VIRUS INFECTION; VIRUS LOAD; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; GENETICS; HUMAN; IMMUNOLOGY; INFLUENZA A VIRUS (H1N1); INTRANASAL DRUG ADMINISTRATION; LUNG; PATHOLOGY; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; ULTRASTRUCTURE; VIROLOGY;

MUS; ORTHOMYXOVIRIDAE; RESPIRATORY SYNCYTIAL VIRUS; RICE STRIPE VIRUS;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; EPITOPES; FORMALDEHYDE; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INTERFERON-GAMMA; INTERLEUKIN-4; LUNG; MICE; MICE, INBRED BALB C; RECOMBINANT FUSION PROTEINS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUSES; VACCINES, INACTIVATED;

EID: 84920098436     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2014.12.009     Document Type: Article

References (46)

1. Arbiza, J., Taylor, G., Lopez, J.A., Furze, J., Wyld, S., Whyte, P., Stott, E.J., Wertz, G., Sullender, W., Trudel, M., et al., 1992. Characterization of two antigenic sites recognized by neutralizing monoclonal antibodies directed against the fusion glycoprotein of human respiratory syncytial virus. J. Gen. Virol. 73 (Pt 9), 2225-2234.
2. Bian, C., Liu, S., Liu, N., Zhang, G., Xing, L., Song, Y., Duan, Y., Gu, H., Zhou, Y., Zhang, P., Li, Z., Zhang, K., Wang, Z., Zhang, S., Wang, X., Yang, P., 2014. Influenza virus vaccine expressing fusion and attachment protein epitopes of respiratory syncytial virus induces protective antibodies in BALB/c mice. Antiviral Res. 104, 110-117.
3. Blanco, J.C., Boukhvalova, M.S., Pletneva, L.M., Shirey, K.A., Vogel, S.N., 2014. A recombinant anchorless respiratory syncytial virus (RSV) fusion (F) protein/monophosphoryl lipid A (MPL) vaccine protects against RSV-induced replication and lung pathology. Vaccine 32, 1495-1500.
4. Carbonell-Estrany, X., Simoes, E.A., Dagan, R., Hall, C.B., Harris, B., Hultquist, M., Connor, E.M., Losonsky, G.A., 2010. Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial. Pediatrics 125, e35-e51.
5. Castilow, E.M., Olson, M.R., Meyerholz, D.K., Varga, S.M., 2008. Differential role of gamma interferon in inhibiting pulmonary eosinophilia and exacerbating systemic disease in fusion protein-immunized mice undergoing challenge infection with respiratory syncytial virus. J. Virol. 82, 2196-2207.
6. Castilow, E.M., Varga, S.M., 2008. Overcoming T cell-mediated immunopathology to achieve safe RSV vaccination. Future Virol. 3, 445-454.
7. Cherukuri, A., Stokes, K.L., Patton, K., Kuo, H., Sakamoto, K., Lambert, S., Stillman, E., Moore, M.L., Lee, S., 2012. An adjuvanted respiratory syncytial virus fusion protein induces protection in aged BALB/c mice. Immun. Ageing 9, 21.
8. Cox, R.J., Brokstad, K.A., Ogra, P., 2004. Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand. J. Immunol. 59, 1-15.
9. Crowe Jr., J.E., Bui, P.T., Davis, A.R., Chanock, R.M., Murphy, B.R., 1994. A further attenuated derivative of a cold-passaged temperature-sensitive mutant of human respiratory syncytial virus retains immunogenicity and protective efficacy against wild-type challenge in seronegative chimpanzees. Vaccine 12, 783-790.
10. Crowe Jr., J.E., Collins, P.L., London, W.T., Chanock, R.M., Murphy, B.R., 1993. A comparison in chimpanzees of the immunogenicity and efficacy of live attenuated respiratory syncytial virus (RSV) temperature-sensitive mutant vaccines and vaccinia virus recombinants that express the surface glycoproteins of RSV. Vaccine 11, 1395-1404.
11. De Baets, S., Schepens, B., Sedeyn, K., Schotsaert, M., Roose, K., Bogaert, P., Fiers, W., Saelens, X., 2013. Recombinant influenza virus carrying the respiratory syncytial virus (RSV) F85-93 CTL epitope reduces RSV replication in mice. J. Virol. 87, 3314-3323.
12. Falsey, A.R., Hennessey, P.A., Formica, M.A., Cox, C., Walsh, E.E., 2005. Respiratory syncytial virus infection in elderly and high-risk adults. N. Engl. J. Med. 352, 1749-1759.
13. Garg, R., Latimer, L., Gerdts, V., Potter, A., van Drunen Littel-van den Hurk, S., 2014. Vaccination with the RSV fusion protein formulated with a combination adjuvant induces long-lasting protective immunity. J. Gen. Virol. 95, 1043-1054.
14. Haller, A.A., Mitiku, M., MacPhail, M., 2003. Bovine parainfluenza virus type 3 (PIV3) expressing the respiratory syncytial virus (RSV) attachment and fusion proteins protects hamsters from challenge with human PIV3 and RSV. J. Gen. Virol. 84, 2153-2162.
15. Hatziioannou, T., Delahaye, E., Martin, F., Russell, S.J., Cosset, F.L., 1999. Retroviral display of functional binding domains fused to the amino terminus of influenza hemagglutinin. Hum. Gene Ther. 10, 1533-1544.
16. Hoffmann, E., Neumann, G., Kawaoka, Y., Hobom, G., Webster, R.G., 2000. A DNA transfection system for generation of influenza A virus from eight plasmids. Proc. Natl. Acad. Sci. U.S.A. 97, 6108-6113.
17. Hsu, K.H., Lubeck, M.D., Davis, A.R., Bhat, R.A., Selling, B.H., Bhat, B.M., Mizutani, S., Murphy, B.R., Collins, P.L., Chanock, R.M., et al., 1992. Immunogenicity of recombinant adenovirus-respiratory syncytial virus vaccines with adenovirus types 4, 5, and 7 vectors in dogs and a chimpanzee. J. Infect. Dis. 166, 769-775.
18. Huang, K., Incognito, L., Cheng, X., Ulbrandt, N.D., Wu, H., 2010. Respiratory syncytial virus-neutralizing monoclonal antibodies motavizumab and palivizumab inhibit fusion. J. Virol. 84, 8132-8140.
19. IMpact-RSV-Study-Group, 1998. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 102, 531-537.
20. Jafri, H.S., Chavez-Bueno, S., Mejias, A., Gomez, A.M., Rios, A.M., Nassi, S.S., Yusuf, M., Kapur, P., Hardy, R.D., Hatfield, J., Rogers, B.B., Krisher, K., Ramilo, O., 2004. Respiratory syncytial virus induces pneumonia, cytokine response, airway obstruction, and chronic inflammatory infiltrates associated with long-term airway hyperresponsiveness in mice. J. Infect. Dis. 189, 1856-1865.
21. Johnson, J.E., McNeil, L.K., Megati, S., Witko, S.E., Roopchand, V.S., Obregon, J.H., Illenberger, D.M., Kotash, C.S., Nowak, R.M., Braunstein, E., Yurgelonis, I., Jansen, K.U., Kalyan, N.K., Sidhu, M.K., 2013. Non-propagating, recombinant vesicular stomatitis virus vectors encoding respiratory syncytial virus proteins generate potent humoral and cellular immunity against RSV and are protective in mice. Immunol. Lett. 150, 134-144.
22. Johnson, T.R., Rangel, D., Graham, B.S., Brough, D.E., Gall, J.G., 2014. Genetic vaccine for respiratory syncytial virus provides protection without disease potentiation. Mol. Ther. 22, 196-205.
23. Kang, S.M., Guo, L., Yao, Q., Skountzou, I., Compans, R.W., 2004. Intranasal immunization with inactivated influenza virus enhances immune responses to coadministered simian-human immunodeficiency virus-like particle antigens. J. Virol. 78, 9624-9632.
24. Karron, R.A., Wright, P.F., Belshe, R.B., Thumar, B., Casey, R., Newman, F., Polack, F.P., Randolph, V.B., Deatly, A., Hackell, J., Gruber, W., Murphy, B.R., Collins, P.L., 2005. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J. Infect. Dis. 191, 1093-1104.
25. Kim, E., Okada, K., Beeler, J.A., Crim, R.L., Piedra, P.A., Gilbert, B.E., Gambotto, A., 2014. Development of an adenovirus-based respiratory syncytial virus vaccine: preclinical evaluation of efficacy, immunogenicity, and enhanced disease in a cotton rat model. J. Virol. 88, 5100-5108.
26. Kim, H.W., Canchola, J.G., Brandt, C.D., Pyles, G., Chanock, R.M., Jensen, K., Parrott, R.H., 1969. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol. 89, 422-434.
27. Kreijtz, J.H., Fouchier, R.A., Rimmelzwaan, G.F., 2011. Immune responses to influenza virus infection. Virus Res. 162, 19-30.
28. Kwon, Y.M., Hwang, H.S., Lee, J.S., Ko, E.J., Yoo, S.E., Kim, M.C., Lee, Y.N., Kim, K.H., Song, J.M., Lee, S., Moore, M.L., Kang, S.M., 2014. Maternal antibodies by passive immunization with formalin inactivated respiratory syncytial virus confer protection without vaccine-enhanced disease. Antiviral Res. 104, 1-6.
29. Li, Z.N., Mueller, S.N., Ye, L., Bu, Z., Yang, C., Ahmed, R., Steinhauer, D.A., 2005. Chimeric influenza virus hemagglutinin proteins containing large domains of the Bacillus anthracis protective antigen: protein characterization, incorporation into infectious influenza viruses, and antigenicity. J. Virol. 79, 10003-10012.
30. Liang, B., Munir, S., Amaro-Carambot, E., Surman, S., Mackow, N., Yang, L., Buchholz, U.J., Collins, P.L., Schaap-Nutt, A., 2014. Chimeric bovine/human parainfluenza virus type 3 expressing respiratory syncytial virus (RSV) F glycoprotein: effect of insert position on expression, replication, immunogenicity, stability, and protection against RSV infection. J. Virol. 88, 4237-4250.
31. McLellan, J.S., Yang, Y., Graham, B.S., Kwong, P.D., 2011. Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes. J. Virol. 85, 7788-7796.
32. Meyerholz, D.K., Griffin, M.A., Castilow, E.M., Varga, S.M., 2009. Comparison of histochemical methods for murine eosinophil detection in an RSV vaccine-enhanced inflammation model. Toxicol. Pathol. 37, 249-255.
33. Murata, Y., Catherman, S.C., 2012. Antibody response to the central unglycosylated region of the respiratory syncytial virus attachment protein in mice. Vaccine 30, 5382-5388.
34. Murphy, B.R., Sotnikov, A.V., Lawrence, L.A., Banks, S.M., Prince, G.A., 1990. Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization. Vaccine 8, 497-502.
35. Nair, H., Nokes, D.J., Gessner, B.D., Dherani, M., Madhi, S.A., Singleton, R.J., O'Brien, K.L., Roca, A., Wright, P.F., Bruce, N., Chandran, A., Theodoratou, E., Sutanto, A., Sedyaningsih, E.R., Ngama, M., Munywoki, P.K., Kartasasmita, C., Simoes, E.A., Rudan, I., Weber, M.W., Campbell, H., 2010. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 375, 1545-1555.
36. Nguyen, T.N., Power, U.F., Robert, A., Haeuw, J.F., Helffer, K., Perez, A., Asin, M.A., Corvaia, N., Libon, C., 2012. The respiratory syncytial virus G protein conserved domain induces a persistent and protective antibody response in rodents. PLoS ONE 7, e34331.
37. Olmsted, R.A., Elango, N., Prince, G.A., Murphy, B.R., Johnson, P.R., Moss, B., Chanock, R.M., Collins, P.L., 1986. Expression of the F glycoprotein of respiratory syncytial virus by a recombinant vaccinia virus: comparison of the individual contributions of the F and G glycoproteins to host immunity. Proc. Natl. Acad. Sci. U.S.A. 83, 7462-7466.
38. Piedra, P.A., Grace, S., Jewell, A., Spinelli, S., Bunting, D., Hogerman, D.A., Malinoski, F., Hiatt, P.W., 1996. Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis. Pediatr. Infect. Dis. J. 15, 23-31.
39. Prince, G.A., Curtis, S.J., Yim, K.C., Porter, D.D., 2001. Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with Lot 100 or a newly prepared reference vaccine. J. Gen. Virol. 82, 2881-2888.
40. Schmidt, M.R., McGinnes, L.W., Kenward, S.A., Willems, K.N., Woodland, R.T., Morrison, T.G., 2012. Long-term and memory immune responses in mice against Newcastle disease virus-like particles containing respiratory syncytial virus glycoprotein ectodomains. J. Virol. 86, 11654-11662.
41. Smith, G., Raghunandan, R., Wu, Y., Liu, Y., Massare, M., Nathan, M., Zhou, B., Lu, H., Boddapati, S., Li, J., Flyer, D., Glenn, G., 2012. Respiratory syncytial virus fusion glycoprotein expressed in insect cells form protein nanoparticles that induce protective immunity in cotton rats. PLoS ONE 7, e50852.
42. Stevens, W.W., Kim, T.S., Pujanauski, L.M., Hao, X., Braciale, T.J., 2007. Detection and quantitation of eosinophils in the murine respiratory tract by flow cytometry. J. Immunol. Methods 327, 63-74.
43. Vaux-Peretz, F., Chapsal, J.M., Meignier, B., 1992. Comparison of the ability of formalin-inactivated respiratory syncytial virus, immunopurified F, G and N proteins and cell lysate to enhance pulmonary changes in Balb/c mice. Vaccine 10, 113-118.
44. Wright, P.F., Karron, R.A., Madhi, S.A., Treanor, J.J., King, J.C., O'Shea, A., Ikizler, M.R., Zhu, Y., Collins, P.L., Cutland, C., Randolph, V.B., Deatly, A.M., Hackell, J.G., Gruber, W.C., Murphy, B.R., 2006. The interferon antagonist NS2 protein of respiratory syncytial virus is an important virulence determinant for humans. J. Infect. Dis. 193, 573-581.
45. Wu, H., Pfarr, D.S., Johnson, S., Brewah, Y.A., Woods, R.M., Patel, N.K., White, W.I., Young, J.F., Kiener, P.A., 2007. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J. Mol. Biol. 368, 652-665.
46. Wyatt, L.S., Whitehead, S.S., Venanzi, K.A., Murphy, B.R., Moss, B., 1999. Priming and boosting immunity to respiratory syncytial virus by recombinant replication-defective vaccinia virus MVA. Vaccine 18, 392-397.